US 11,692,044 B2
Compositions and methods for the treatment of systemic inflammatory response syndromes
Jordan Marshall Sand, Madison, WI (US); Mark Eric Cook, Madison, WI (US); and Daniel Elmer Butz, Madison, WI (US)
Assigned to WISCONSIN ALUMNI RESEARCH FOUNDATION, Madison, WI (US)
Filed by Wisconsin Alumni Research Foundation, Madison, WI (US)
Filed on Apr. 14, 2017, as Appl. No. 15/487,619.
Application 15/487,619 is a division of application No. 13/667,346, filed on Nov. 2, 2012, granted, now 9,657,109.
Prior Publication US 2017/0218089 A1, Aug. 3, 2017
Int. Cl. C07K 16/40 (2006.01); C07K 5/113 (2006.01); C12N 9/20 (2006.01); A23K 20/147 (2016.01); A23L 33/17 (2016.01); A61K 39/00 (2006.01)
CPC C07K 16/40 (2013.01) [A23K 20/147 (2016.05); A23L 33/17 (2016.08); C07K 5/1021 (2013.01); C12N 9/20 (2013.01); C12Y 301/01004 (2013.01); A23V 2002/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/11 (2013.01); C07K 2317/23 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01)] 8 Claims
 
1. A method of reducing the contribution of the gastrointestinal tract to an inflammatory process, comprising
orally administering to an individual in need thereof an antibody that specifically binds secretory phospholipase A2-IB, wherein the antibody specifically binds a peptide consisting of (V/A/R)PYNK(A/E)(H/Y)K (SEQ ID NO. 6), wherein the antibody is a polyclonal avian egg yolk IgY antibody preparation produced by inoculating laying hens with the peptide.